The relationship between Nuclear Factor-Kappa B and Inhibitor-Kappa B parameters with clinical course in COVID-19 patients.
Humans
COVID-19
/ blood
Male
Female
Middle Aged
Biomarkers
/ blood
SARS-CoV-2
C-Reactive Protein
/ metabolism
Adult
NF-KappaB Inhibitor alpha
/ metabolism
Transcription Factor RelA
/ metabolism
Aged
NF-kappa B p50 Subunit
/ metabolism
NF-kappa B
/ metabolism
ROC Curve
Fibrin Fibrinogen Degradation Products
/ metabolism
Ferritins
/ blood
COVID-19
IκBα
NF-κB
Oxygen (O2) requirement
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
15 Jul 2024
15 Jul 2024
Historique:
received:
13
04
2024
accepted:
14
06
2024
medline:
15
7
2024
pubmed:
15
7
2024
entrez:
15
7
2024
Statut:
epublish
Résumé
We aimed to investigate the serum Nuclear Factor Kappa B (NF-κB) p105, NF-κB p65 and Inhibitor Kappa B Alpha (IκBα) levels in patients with mild/moderate Coronavirus Disease 2019 (COVID-19) and their association with the course of the disease. Blood was drawn from 35 COVID-19 patients who applied to the Department of Emergency Medicine of Istanbul University-Cerrahpasa at the time of diagnosis and from 35 healthy individuals. The patients were evaluated to have mild/moderate degree of disease according to National Early Warning Score 2 (NEWS2) scoring and computed tomography (CT) findings. The markers were studied in the obtained serum samples, using enzyme-linked immunoassay (ELISA). Receiver Operating Characteristic (ROC) analysis was performed. Statistical significance was evaluated to be p < 0.05. NF-κB p105 levels were significantly higher in the COVID-19 group compared to the control group. C-reactive protein (CRP), D-dimer, ferritin levels of the patients were significantly higher (p < 0.001) compared to the control group, while the lymphocyte count was found lower (p = 0.001). IκBα and NF-κB p65 levels are similar in both groups. Threshold value for NF-κB p105 was above 0.78 ng/mL, sensitivity was 71.4% and specificity was 97.1% (p < 0.05). NF-κB p105 levels at the time of diagnosis of the patients who required supplemental oxygen (O The rise in serum NF-κB p105 levels during the early stages of infection holds diagnostic value. Besides its relation with severity might have a prognostic feature to foresee the requirement for supplemental O
Sections du résumé
BACKGROUND
BACKGROUND
We aimed to investigate the serum Nuclear Factor Kappa B (NF-κB) p105, NF-κB p65 and Inhibitor Kappa B Alpha (IκBα) levels in patients with mild/moderate Coronavirus Disease 2019 (COVID-19) and their association with the course of the disease.
MATERIALS AND METHODS
METHODS
Blood was drawn from 35 COVID-19 patients who applied to the Department of Emergency Medicine of Istanbul University-Cerrahpasa at the time of diagnosis and from 35 healthy individuals. The patients were evaluated to have mild/moderate degree of disease according to National Early Warning Score 2 (NEWS2) scoring and computed tomography (CT) findings. The markers were studied in the obtained serum samples, using enzyme-linked immunoassay (ELISA). Receiver Operating Characteristic (ROC) analysis was performed. Statistical significance was evaluated to be p < 0.05.
RESULTS
RESULTS
NF-κB p105 levels were significantly higher in the COVID-19 group compared to the control group. C-reactive protein (CRP), D-dimer, ferritin levels of the patients were significantly higher (p < 0.001) compared to the control group, while the lymphocyte count was found lower (p = 0.001). IκBα and NF-κB p65 levels are similar in both groups. Threshold value for NF-κB p105 was above 0.78 ng/mL, sensitivity was 71.4% and specificity was 97.1% (p < 0.05). NF-κB p105 levels at the time of diagnosis of the patients who required supplemental oxygen (O
CONCLUSIONS
CONCLUSIONS
The rise in serum NF-κB p105 levels during the early stages of infection holds diagnostic value. Besides its relation with severity might have a prognostic feature to foresee the requirement for supplemental O
Identifiants
pubmed: 39008220
doi: 10.1007/s11033-024-09729-6
pii: 10.1007/s11033-024-09729-6
doi:
Substances chimiques
Biomarkers
0
C-Reactive Protein
9007-41-4
NF-KappaB Inhibitor alpha
139874-52-5
Transcription Factor RelA
0
NF-kappa B p50 Subunit
0
NF-kappa B
0
Fibrin Fibrinogen Degradation Products
0
fibrin fragment D
0
NFKBIA protein, human
0
Ferritins
9007-73-2
RELA protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
813Subventions
Organisme : Istanbul Üniversitesi-Cerrahpasa
ID : 35680
Organisme : Istanbul Üniversitesi-Cerrahpasa
ID : 35680
Organisme : Istanbul Üniversitesi-Cerrahpasa
ID : 35680
Organisme : Istanbul Üniversitesi-Cerrahpasa
ID : 35680
Organisme : Istanbul Üniversitesi-Cerrahpasa
ID : 35680
Organisme : Istanbul Üniversitesi-Cerrahpasa
ID : 35680
Organisme : Istanbul Üniversitesi-Cerrahpasa
ID : 35680
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X et al (2020) Clinical features of patients infected with 2019 Novel Coronavirus in Wuhan, China. Lancet 395:497–506. https://doi.org/10.1016/S0140-6736(20)30183-5
doi: 10.1016/S0140-6736(20)30183-5
pubmed: 31986264
pmcid: 7159299
Hirano T, Murakami M (2020) COVID-19: a new virus, but a familiar receptor and cytokine release syndrome. Immunity 52:731–733. https://doi.org/10.1016/j.immuni.2020.04.003
doi: 10.1016/j.immuni.2020.04.003
pubmed: 32325025
pmcid: 7175868
World Health Organization (2020) COVID-19 timeline. https://www.who.int/news/item/27-04-2020who-timeline---covid-19 Accessed 22 May 2024
Osuchowski MF, Winkler MS, Skirecki T, Cajander S, Shankar-Hari M, Lachmann G, Monneret G, Venet F, Bauer M, Brunkhorst FM et al (2021) The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respir Med 9:622–642. https://doi.org/10.1016/S2213-2600(21)00218-6
doi: 10.1016/S2213-2600(21)00218-6
pubmed: 33965003
pmcid: 8102044
Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, Vanstapel A, Werlein C, Stark H, Tzankov A et al (2020) Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med 383:120–128. https://doi.org/10.1056/NEJMoa2015432
doi: 10.1056/NEJMoa2015432
pubmed: 32437596
pmcid: 7412750
de Wit E, van Doremalen N, Falzarano D, Munster VJ, SARS (2016) Recent insights into emerging coronaviruses. Nat Rev Microbiol 14:523–534. https://doi.org/10.1038/nrmicro.2016.81
doi: 10.1038/nrmicro.2016.81
pubmed: 27344959
pmcid: 7097822
Coronavirus Cases and Clinical Presentation (2024) https://emedicine.medscape.com/article/2500114-clinical?form=fpf . Accessed 22 May 2024
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395:1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3
doi: 10.1016/S0140-6736(20)30566-3
pubmed: 32171076
pmcid: 7270627
Jin Y-H, Cai L, Cheng Z-S, Cheng H, Deng T, Fan Y-P, Fang C, Huang D, Huang L-Q, Huang Q et al (2020) A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-NCoV) infected pneumonia (Standard Version). Mil Med Res 7(4). https://doi.org/10.1186/s40779-020-0233-6
World Health Organization (2020) Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance, 13 March 2020. World Health Organization. https://iris.who.int/handle/10665/331446 . Accessed 22 May 2024
National Institutes of Health-Clinical Spectrum of SARS-CoV-2 Infection (2024) https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/ . Accessed 22 May 2024
Baker KF, Hanrath AT, van der Loeff IS, Kay LJ, Back J, Duncan CJA (2021) National early warning score 2 (NEWS2) to identify inpatient COVID-19 deterioration: a retrospective analysis. Clin Med J R Coll Physicians Lond 21:84–89. https://doi.org/10.7861/CLINMED.2020-0688
doi: 10.7861/CLINMED.2020-0688
Liao Q-J, Ye L-B, Timani KA, Zeng Y-C, She Y-L, Ye L, Wu Z-H (2005) Activation of NF-KappaB by the full-length nucleocapsid protein of the SARS Coronavirus. Acta Biochim Biophys Sin (Shanghai) 37:607–612. https://doi.org/10.1111/j.1745-7270.2005.00082.x
doi: 10.1111/j.1745-7270.2005.00082.x
pubmed: 16143815
Ghosh S, Hayden MS (2008) New regulators of NF-ΚB in inflammation. Nat Rev Immunol 8:837–848. https://doi.org/10.1038/nri2423
doi: 10.1038/nri2423
pubmed: 18927578
Hayden MS, Ghosh S (2012) NF-ΚB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev 26:203–234. https://doi.org/10.1101/gad.183434.111
doi: 10.1101/gad.183434.111
pubmed: 22302935
pmcid: 3278889
Hinz M, Scheidereit C (2014) The IκB kinase complex in < scp > NF -κB regulation and beyond. EMBO Rep 15:46–61. https://doi.org/10.1002/embr.201337983
doi: 10.1002/embr.201337983
pubmed: 24375677
Liu T, Zhang L, Joo D, Sun S-C (2017) NF-ΚB signaling in inflammation. Signal Transduct Target Ther 2:17023. https://doi.org/10.1038/sigtrans.2017.23
doi: 10.1038/sigtrans.2017.23
pubmed: 29158945
pmcid: 5661633
Elkhodary MSM (2020) Treatment of COVID-19 by controlling the activity of the nuclear factor-Kappa B. CellBio 09:109–121. https://doi.org/10.4236/cellbio.2020.92006
doi: 10.4236/cellbio.2020.92006
Farahani M, Niknam Z, Mohammadi Amirabad L, Amiri-Dashatan N, Koushki M, Nemati M, Danesh Pouya F, Rezaei-Tavirani M, Rasmi Y, Tayebi L (2022) Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets. Biomed Pharmacother 145. https://doi.org/10.1016/j.biopha.2021.112420
Hojyo S, Uchida M, Tanaka K, Hasebe R, Tanaka Y, Murakami M, Hirano T (2020) How COVID-19 induces cytokine storm with high mortality. Inflamm Regen 40:37. https://doi.org/10.1186/s41232-020-00146-3
doi: 10.1186/s41232-020-00146-3
pubmed: 33014208
pmcid: 7527296
Yang Y, Shen C, Li J, Yuan J, Yang M, Wang F, Li G, Li Y, Xing L, Peng L et al (2020) Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS-CoV-2 infection is associated with disease severity and fatal outcome. medRxiv 2, 2020.03.02.20029975
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395:1033–1034. https://doi.org/10.1016/S0140-6736(20)30628-0
doi: 10.1016/S0140-6736(20)30628-0
pubmed: 32192578
pmcid: 7270045
Kircheis R, Haasbach E, Lueftenegger D, Heyken WT, Ocker M, Planz O (2020) NF-ΚB pathway as a potential target for treatment of critical stage COVID-19 patients. Front Immunol 11:1–11. https://doi.org/10.3389/fimmu.2020.598444
doi: 10.3389/fimmu.2020.598444
Barnabei L, Laplantine E, Mbongo W, Rieux-Laucat F, Weil R (2021) NF-ΚB: at the borders of autoimmunity and inflammation. Front Immunol 12:1–27. https://doi.org/10.3389/fimmu.2021.716469
doi: 10.3389/fimmu.2021.716469
Robles JP, Zamora M, Adan-Castro E, Siqueiros-Marquez L, de la Martinez G, Clapp C (2022) The spike protein of SARS-CoV-2 induces endothelial inflammation through integrin Α5β1 and NF-ΚB signaling. J Biol Chem 298. https://doi.org/10.1016/j.jbc.2022.101695
Sohn KM, Lee SG, Kim HJ, Cheon S, Jeong H, Lee J, Kim IS, Silwal P, Kim YJ, Paik S et al (2020) COVID-19 patients upregulate toll-like receptor 4-mediated inflammatory signaling that mimics bacterial sepsis. J Korean Med Sci 35:e343. https://doi.org/10.3346/jkms.2020.35.e343
doi: 10.3346/jkms.2020.35.e343
pubmed: 32989935
pmcid: 7521960
Kalemci S, Zeybek A, Kargi AB (2022) Can the development of lung fibrosis be prevented after COVID-19 infection? Kardiochirurgia i Torakochirurgia Pol 19:113. https://doi.org/10.5114/kitp.2022.117505
doi: 10.5114/kitp.2022.117505
Fangradt M, Hahne M, Gaber T, Strehl C, Rauch R, Hoff P, Löhning M, Burmester G-R, Buttgereit F (2012) Human monocytes and macrophages differ in their mechanisms of adaptation to hypoxia. Arthritis Res Ther 14. https://doi.org/10.1186/ar4011
Kadhim AS, Abdullah YJ Serum Levels of Interleukin-6, Ferritin, Protein C-R, Dehydrogenase L (2021) D-Dimer, and count of lymphocytes and neutrophils in COVID-19 patients: its correlation to the disease severity. Biomed Biotechnol Res J 5:69–73. https://doi.org/10.4103/bbrj.bbrj_188_20
Balcı S, Poyraz Z, Gülüm C, Aslan G, Tamer L, Çimen MB (2021) Erken Evre COVİD-19 Hastalarında Biyokimyasal Parametrelerin Değerlendirilmesi. Mersin Üniversitesi Sağlık Bilim Derg 14:378–384. https://doi.org/10.26559/mersinsbd.959335
doi: 10.26559/mersinsbd.959335
Tufa A, Gebremariam TH, Manyazewal T, Getinet T, Webb D-L, Hellström PM, Genet S (2022) Inflammatory mediators profile in patients hospitalized with COVID-19: a comparative study. Front Immunol 13:1–14. https://doi.org/10.3389/fimmu.2022.964179
doi: 10.3389/fimmu.2022.964179
Zhou Q, Zhang L, Dong Y et al (2024) The role of SARS-CoV-2-mediated NF-κB activation in COVID-19 patients. Hypertens Res 47:375–384. https://doi.org/10.1038/s41440-023-01460-2
doi: 10.1038/s41440-023-01460-2
pubmed: 37872376
Lai KY, Au SY, Sin KC, Yung SK, Leung AKH (2024) High-dose N-acetylcysteine in an immunocompromised patient with COVID-19: a case report. Hong Kong Med J 30(1):69–71. https://doi.org/10.12809/hkmj2210461 Epub 2024 Feb 8. PMID: 38327160
doi: 10.12809/hkmj2210461
pubmed: 38327160